Quality of individual INR control and the risk of stroke and bleeding events in atrial fibrillation patients: A nested case control analysis of the ACTIVE W study

被引:38
作者
Nieuwlaat, Robby [1 ]
Connolly, Benjamin J. [1 ]
Hubers, Lowiek M. [1 ]
Cuddy, Spencer M. [1 ]
Eikelboom, John W. [1 ]
Yusuf, Salim [1 ]
Connolly, Stuart J. [1 ]
机构
[1] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON L8L 2X2, Canada
关键词
Anticoagulation; Quality of care; Patient outcomes; Atrial fibrillation; ANTICOAGULATION CONTROL; ORAL ANTICOAGULANT; CLOPIDOGREL TRIAL; PREVENTION; THERAPY; IRBESARTAN; INTENSITY; WARFARIN;
D O I
10.1016/j.thromres.2011.08.024
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Time in therapeutic range (TTR) for international normalized ratio (INR) is an accepted quality measure of anticoagulation control in patient populations, but its usefulness for predicting stroke and bleeding in individuals is not well understood. Materials and Methods: In a nested case control analysis among ACTIVE W study patients, cases with stroke and cases with bleeding were separately matched with controls. Several anticoagulation quality measures were compared, overall and in a time-dependent manner. Results: 32 cases with ischemic stroke and 234 cases with bleeding in the analysis were matched in a 4:1 ratio to 122 and 865 controls, respectively. Follow-up duration was 257 +/- 154 days for the stroke analysis and 222 +/- 146 days for the bleeding analysis. Compared with their respective controls, the study mean TTR of both stroke cases (53.9%+/- 25.1 vs 63.4%+/- 24.8; p=0.055) and bleeding cases (56.2%+/- 25.4 vs 63.4%+/- 26.8; p<0.001) was lower. Time below range for stroke and time above range for bleeding were only greater in the last month leading up to the event, not over the entire study period. Rather, over the entire study period bleeding cases spent more time below range than controls (26.8%+/- 25.9 vs 20.8%+/- 24.0; p=0.001). Conclusions: TTR was lower in individual AF patients with stroke or bleeding compared with matched controls in ACTIVE W. Maintaining a high TTR, with equal importance to avoid low and high INRs, is a relevant goal of individual patient treatment to prevent stroke and bleeding. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:715 / 719
页数:5
相关论文
共 11 条
[1]   Pharmacology and management of the vitamin K antagonists [J].
Ansell, Jack ;
Hirsh, Jack ;
Hylek, Elaine ;
Jacobson, Alan ;
Crowther, Mark ;
Palareti, Gualtiero .
CHEST, 2008, 133 (06) :160S-198S
[2]   Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial [J].
Connolly, S. ;
Pogue, J. ;
Hart, R. ;
Pfeffer, M. ;
Hohnloser, S. ;
Chrolavicius, S. ;
Yusuf, S. .
LANCET, 2006, 367 (9526) :1903-1912
[3]   Rationale and design of ACTIVE: The atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events [J].
Connolly, S. ;
Yusuf, S. ;
Budaj, A. ;
Camm, J. ;
Chrolavicius, S. ;
Commerford, P. J. ;
Flather, M. ;
Fox, K. A. A. ;
Hart, R. ;
Hohnloser, S. ;
Joyner, C. ;
Pfeffer, M. ;
Anand, I. ;
Arthur, H. ;
Avezum, A. ;
Bethala-Sithya, M. ;
Blumenthal, M. ;
Ceremuzynski, L. ;
De Caterina, R. ;
Diaz, R. ;
Flaker, G. ;
Frangin, G. ;
Franzosi, M. -G. ;
Gaudin, C. ;
Golitsyn, S. ;
Goldhaber, S. ;
Granger, C. ;
Halon, D. ;
Hermosillo, A. ;
Hunt, D. ;
Jansky, P. ;
Karatzas, N. ;
Keltai, M. ;
Lanas, F. ;
Lau, C. P. ;
Le Heuzey, J. -Y. ;
Lewis, B. S. ;
Morais, J. ;
Morillo, C. ;
Oto, A. ;
Paolasso, E. ;
Peters, R. J. ;
Pfisterer, M. ;
Piegas, L. ;
Pipillis, T. ;
Proste, C. ;
Sitkei, E. ;
Swedberg, K. ;
Synhorst, D. ;
Talajic, M. .
AMERICAN HEART JOURNAL, 2006, 151 (06) :1187-1193
[4]   Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range [J].
Connolly, Stuart J. ;
Pogue, Janice ;
Eikelboom, John ;
Flaker, Gregory ;
Commerford, Patrick ;
Franzosi, Maria Grazia ;
Healey, Jeffrey S. ;
Yusuf, Salim .
CIRCULATION, 2008, 118 (20) :2029-2037
[5]   Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation [J].
Hart, Robert G. ;
Pearce, Lesly A. ;
Aguilar, Maria I. .
ANNALS OF INTERNAL MEDICINE, 2007, 146 (12) :857-867
[6]   Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population [J].
Jones, M ;
McEwan, P ;
Morgan, CL ;
Peters, JR ;
Goodfellow, J ;
Currie, CJ .
HEART, 2005, 91 (04) :472-477
[7]   Warfarin treatment in patients with atrial fibrillation: Observing outcomes associated with varying levels of INR control [J].
Morgan, Christopher Ll. ;
McEwan, Phil ;
Tukiendorf, Andrzej ;
Robinson, Paul A. ;
Clemens, Andreas ;
Plumb, Jonathan M. .
THROMBOSIS RESEARCH, 2009, 124 (01) :37-41
[8]  
ROSENDAAL FR, 1993, THROMB HAEMOSTASIS, V69, P236
[9]   Should Patient Characteristics Influence Target Anticoagulation Intensity for Stroke Prevention in Nonvalvular Atrial Fibrillation? The ATRIA Study [J].
Singer, Daniel E. ;
Chang, Yuchiao ;
Fang, Margaret C. ;
Borowsky, Leila H. ;
Pomernacki, Niela K. ;
Udaltsova, Natalia ;
Go, Alan S. .
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2009, 2 (04) :297-U30
[10]   Effect of study setting on anticoagulation control - A systematic review and metaregression [J].
van Walraven, Carl ;
Jennings, Alison ;
Oake, Natalie ;
Fergusson, Dean ;
Forster, Alan J. .
CHEST, 2006, 129 (05) :1155-1166